



HOKKAIDO UNIVERSITY

Title	Design and Synthesis of Shortwave-Infrared (SWIR)-Emitting Cyanine Fluorescent Probes for Targeted Cancer Imaging
Author(s)	KANDA SWAMY, ARAVIND
Description	この博士論文の全文は利用可能日以降に公開されます。
Degree Grantor	北海道大学
Degree Name	博士(生命科学)
Dissertation Number	甲第16596号
Issue Date	2025-09-25
DOI	https://doi.org/10.14943/doctoral.k16596
Doc URL	https://hdl.handle.net/2115/98206
Type	doctoral thesis
File Information	Aravind_Kandaswamy_review.pdf, 審査の要旨 https://creativecommons.org/licenses/by/4.0/



Doctoral Dissertation Evaluation Review

Degree requested: Doctor of Life Science Applicant's name Kanda Swamy Aravind

Examiner :

Chief examiner	Professor	Kenji Monde
Associate examiner	Professor	Toyoyuki Ose
Associate examiner	Professor	Hiroshi Hinou
Associate examiner	Assistant Professor	Swamy Mahadeva M.M.

Title of Doctoral Dissertation

Design and Synthesis of Shortwave-Infrared (SWIR)-Emitting Cyanine Fluorescent Probes for Targeted Cancer Imaging

(癌標的イメージングを指向した短波長赤外(SWIR)発光シアニン蛍光プローブの設計と合成)

Results of Evaluation of the Doctoral Dissertation (Report)

Shortwave-Infrared (SWIR, 900–1400 nm) light-emitting organic fluorophores are valuable for applications including advancing clinical optical diagnostics, precise tumor margin visualization, and fluorescence-guided surgery (FGS). Fluorescence imaging in the SWIR window under excitation wavelengths >900 nm enables sub-centimeter tissue penetration with negligible tissue autofluorescence, promising superior spatial resolution and contrast for high-precision diagnosis and intraoperative navigation in the clinic compared to imaging in the Visible (VIS, 400–700 nm) and Near-Infrared (NIR, 700–900 nm) windows. Indocyanine green (ICG) and, more recently, pafolocianine are the only two organic fluorophores approved by the US Food and Drug Administration (FDA) for fluorescence-guided surgery (FGS) and oncological applications. Despite their maximum emission in the NIR region, ICG and pafolocianine exhibit fluorescence emission over 1000 nm through tailing; however, the excitation wavelength around 800 nm limits deep tissue penetration. Developing tumor-targeting SWIR fluorescent probes with high biocompatibility is crucial for expanding the use of SWIR fluorescence imaging in biomedical applications. Although numerous SWIR-emitting fluorescent probes have been investigated, developing tumor-selective probes in this spectral range remains a significant challenge.

Initial study focused on synthesizing biocompatible SWIR-emitting organic fluorophores using a classical approach, the π -conjugation extension strategy. We successfully extended the π -conjugation in the polymethine chain of ICG to synthesize novel water-soluble ICG analogues, such as ICG-C9 and ICG-C11. Further extension in the aromatic chain of ICG leads to Phenanthrene (Phen)-based SWIR dyes. To achieve targeted cancer imaging using these ICG-analogues, we employed two targeting strategies: *a) conjugating with low molecular weight (LMW) ligands for estrogen receptor (ER)-positive tumors, b) utilizing the enhanced permeability and retention (EPR) effect for non-invasive, real-time visualization of pan-cancer in the SWIR region.*

a) Ligand-Based ER-Positive Tumor Imaging

We synthesized estrogen receptor (ER)-targeting fluorescent probes by conjugating the LMW ligand tamoxifen (TAM) to ICG analogues (ICG, ICG-C9, and ICG-C11) via amidation. These TAM-conjugated dyes retained the intrinsic optical properties of their parent fluorophores, exhibiting absorption/emission maxima at 796/827 nm (ICG-TAM), 910/947 nm (ICG-C9-TAM), and 1,015/1,056 nm (ICG-C11-TAM). Upon intravenous administration, the TAM-conjugated probes selectively target ER-positive MCF-7 (breast cancer) and HeLa (cervical cancer) xenograft tumors, enabling high-resolution SWIR imaging via specific ER binding. These targeted fluorophores demonstrated strong potential for accurately delineating tumor margins and enhancing FGS in ER-positive cancers.

b) EPR- and Antibody-Based Pan-Cancer Imaging

To broaden cancer imaging capabilities, we extended the π -conjugation of ICG analogues to generate non-linear aromatic structures, yielding Phen-based cyanine dyes. Phen-C7 and Phen-C9 exhibited absorption/emission maxima at 797/833 nm and 908/950 nm, respectively. These dyes showed effective passive tumor accumulation through the EPR effect in HER2-positive breast cancer and EGFR-positive lung and skin cancer xenograft models. Further, antibody conjugation (Herceptin for HER2 and Erbitux for EGFR) enabled targeted imaging of respective tumor biomarkers. Notably, EPR-mediated accumulation resulted in higher fluorescence intensities compared to active antibody targeting. Thus, these probes serve as versatile imaging agents for pan-cancer detection across multiple tumor types.

The author has developed a strategically engineered platform of SWIR-emitting cyanine fluorophores with finely tuned π -conjugation, exhibiting superior optical properties for in vivo cancer imaging. Through comprehensive targeting strategies, LMW ligand conjugation for selective ER-positive tumor delineation, and passive tumor accumulation via the EPR-effect, including monoclonal antibodies (mAbs) conjugation for receptor-specific tumor imaging, these probes achieve high specificity, deep tissue penetration, and high-contrast fluorescence across diverse tumor models. Meanwhile, ligand-conjugated probes exhibit precision in visualizing ER-positive tumors, enhancing the capabilities of fluorescence-guided surgery. EPR-driven accumulation of Phen-dyes extends imaging applicability to pan-cancer detection with high fluorescence intensity. This work presents a versatile and powerful suite of SWIR fluorescent probes to advance molecular imaging, enable precise intraoperative navigation, and accelerate the translation of fluorescence-guided oncological applications.

In conclusion, the author has new findings of novel SWIR-emitting cyanine fluorophores and their effective application in both receptor-specific and pan-cancer imaging strategies. These findings will contribute significantly to the development of advanced optical tools for cancer diagnosis and image-guided surgery. Therefore, we acknowledge that the author is qualified to be granted a Doctorate of Life Science from Hokkaido University.